Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safest dose of the investigational medication
Belinostat that can be administered with a standard of care chemotherapy regimen of
bevacizumab, carboplatin, and paclitaxel. Further study will examine the short and long-term
effect (up to 2 years) of this medication on participant's disease status and overall
survival.